siRNA for REST ameliorates symptoms in ALS mice and serum REST predicts disease prognosis and survival in ALS patients.

Mol Ther · 2026 · PMC12925782 · PMID 41108075

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In ALS mice, although siREST treatment showed a trend in preventing body weight loss, especially at the 9th and 10th weeks of testing, it was not significantly effective ( Figure S3 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.